Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Voyager Therapeutics Inc (Voyager) is a biotechnology company that focuses on the development of genetic medicines to treat neurological diseases. The company's pipeline products include VY7523, VY1706, SOD1 Silencing Gene Therapy and Anti-Ab Gene Therapy (Vectorized Antibody) for the treatment of amyotrophic lateral sclerosis, Alzheimer’s disease and multiple other diseases of the central nervous system. The company utilizes TRACER, a platform to identify novel adeno-associated virus (AAV) capsids that deliver gene therapies to specific tissues and cell types. Voyager also developing FXN gene therapy, GBA1 gene therapy, five gene therapy programs and Huntington’s gene therapy in partnership with Neurocrine, Novartis, Alexion, AstraZeneca Rare Disease and Sangamo Therapeutics. Voyager is headquartered in Cambridge, Massachusetts, the US.
Headquarters
United States of America
Address
75 Hayden Avenue, Lexington, Massachusetts, 02421
Website
www.voyagertherapeutics.com
Telephone
1 857 2595340
No of Employees
141
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
VYGR (NASD)
Revenue (2024)
$40.4M
-49.5%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-84.2%
(2024 vs 2023)
Market Cap*
$217.5M
Net Profit Margin (2024)
XYZ
-265.0%
(2024 vs 2023)
* As of and is in US$
Products and Services
| Products | Brands |
|---|---|
| VY7523: Alzheimer’s Disease | TRACER |
| VY1706: Alzheimer’s Disease | |
| SOD1 Silencing Gene Therapy (siRNA) – ALS (Amyotrophic Lateral Sclerosis) | |
| XYZ | |
| XYZ | |
| XYZ |
Competitor Comparison
| Key Parameters | Voyager Therapeutics Inc | Merck & Co Inc | Pfizer Inc | Biogen Inc | Sarepta Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Lexington | Rahway | New York City | Cambridge | Cambridge |
| State/Province | Massachusetts | New Jersey | New York | Massachusetts | Massachusetts |
| No. of Employees | 141 | 75,000 | 75,000 | 7,500 | 835 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Michael Higgins | Chairman | Executive Board | 2019 | 62 |
| Alfred Sandrock, M.D., Ph.D. | Chief Executive Officer; Director; President | Executive Board | 2022 | 67 |
| Robin Swartz | Chief Business Officer; Chief Operating Officer; Principal Financial Officer | Senior Management | 2026 | 55 |
| Jacquelyn Fahey Sandell | Chief Legal Officer | Senior Management | 2023 | 56 |
| Todd Carter, Ph.D. | Chief Scientific Officer | Senior Management | 2022 | 55 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer